GLENMARK · Concall Summary
GLENMARK PHARMACEUTICALS
Concall2026-08-05
Tone: NeutralGlenmark Pharmaceuticals Limited submitted a letter to the National Stock Exchange of India and BSE Limited on August 5, 2026, regarding the transcript of their earnings call held on August 3, 2026. The earnings call discussed the company's performance for the quarter ended June 30, 2026. The transcript has been made available on the company's website for public access. The communication was signed by Rashmi Khandelwal, the Company Secretary and Compliance Officer.
The document presented factual information regarding the earnings call and its transcript.
View source filing →Earlier concalls
- 2026-06-09 — Glenmark Pharmaceuticals Limited communicated the details of its Investor Day Presentation scheduled for June 9, 2026. T…
- 2026-05-29 — Glenmark Pharmaceuticals Limited reported consolidated revenue of Rs. 37,706 million for Q4 FY26, reflecting a year-on-y…
- 2026-02-04 — Glenmark Pharmaceuticals Limited submitted a transcript of its earnings call held on February 2, 2026, regarding the thi…
See GLENMARK's full Research Pro page — annual report summary, insider trades, promoter pledge trend, options positioning and Ask-RedixFi AI.
Sign up free